CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells

Journal of Immunology

Volumn 170, Issue 6, 2003, Pages 3187-3194

  Khanolkar, Aaruni ^a   Fu, Zheng ^a   Underwood, L Joey ^a   Bondurant, Kristy L ^a   Rochford, Rosemary ^b   Cannon, Martin J ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSACTIVATION; VIRUS EXPRESSION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSFORMATION;

EID: 0037443422     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.6.3187     Document Type: Article

References (63)

1. Babcock, G. J., L. L. Decker, M. Volk, and D. A. Thorley-Lawson. 1988. EBV persistence in memory B cells in vivo. Immunity 9:395.
2. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387.
3. Rickinson, A. B., S. P. Lee, and N. M. Steven. 1996. Cytotoxic T lymphocyte response to Epstein-Barr virus. Curr. Opin. Immunol. 8:492.
4. Crawford, D. H., P. Sweny, J. M. Edwards, G. Janossy, and A. V. Hoffbrand. 1981. Long-term T-cell mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A. Lancet 1:10.
5. Gaston, J. S. H., A. B. Rickinson, and M. A. Epstein. 1982. Epstein-Barr virus-specific T-cell memory in renal-allograft recipients under long-term immunosup-pression. Lancet 1:928.
6. Hanto, D. W., G. Frizzera, K. J. Gajl-Peczalska, and R. L. Simmons. 1985. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 39:461.
7. Nalesnik, M. A. 1996. Posttransplantation lymphoproliferative disorders: current perspectives. Semin. Thorac. Cardiovasc. Surg. 8:139.
8. Randhawa, P. S., S. A. Yousem, I. L. Paradis, J. A. Dauber, B. P. Griffith, and J. Locker. 1989. The clinical spectrum, pathology, and clonal analysis of Epstein-Barr virus-associated lymphoproliferative disorders in heart-lung transplant patients. Am. J. Clin. Pathol. 92:177.
9. Boyle, T. J., K. R. Berend, J. M. DiMaio, R. E. Coles, D. F. Via, and H. K. Lyerly. 1993. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. Surgery 114:218.
10. Lacerda, J. F., M. Ladanyi, D. C. Louie, J. M. Fernandez, E. B. Papadopoulos, and R. J. O'Reilly. 1996. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice. J. Exp. Med. 183:1215.
11. + cytotoxic T cells against Epstein-Barr virus-immortalized B cell tumors in SCID mice. Transplantation 58:629.
12. Rooney, C. M., C. A. Smith, C. Y. C. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9.
13. Rooney, C. M., C. A. Smith, C, Y. C. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner, and H. E. Heslop. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549.
14. + T cells. Virology 287:79.
15. Misko, I. S., J. H. Pope. R. Hutter, T. D. Soszynski, and R. G. Kane. 1984. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int. J. Cancer 33:239.
16. + T cells inhibit growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand-mediated apoptosis. Int. Immunol. 10:1149.
17. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J. Exp. Med. 191:1649.
18. Coles, R. E., T. J. Boyle, J. M. DiMaio, K. R. Berend, D. F. Via, and H. K. Lyerly. 1994. T cells or active Epstein-Barr virus infection in the development of lymphoproliferative disease in human B cell-injected severe combined immunodeficient mice. Ann. Surg. Oncol. 1:405.
19. Veronese, M. L., A. Veronesi, E. D'Andrea, A. Del Mistro, S. Indraccolo, M. R. Mazza, M. Mion, R. Zamarchi, C. Menin, M. Panozzo, et al. 1992. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation. J. Exp. Med. 176:1763.
20. + T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J. Virol. 74:6675.
21. Rickinson, A. B., M. Rowe, I. J. Hart, Q. Y. Yao, L. E. Henderson, H. Rabin, and M. A. Epstein. 1984. T-cell-mediated regression of 'spontaneous' and of Epstein-Barr virus-induced B-cell transformation in vitro: studies with cyclosporin A. Cell Immunol. 87:646.
22. Yao, Q. Y., H. Czamecka, and A. B. Rickinson. 1991. Spontaneous outgrowth of Epstein-Barr virus-positive B-cell lines from circulating human B cells of different buoyant densities. Int. J. Cancer 48:253.
23. Garnier, J. L., N. R. Cooper, and M. J. Cannon. 1993. Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice. Am. J. Pathol. 142:353.
24. Pisa, P., M. J. Cannon, E. K. Pisa, N. R. Cooper, and R. I. Fox. 1992. Epstein-Barr virus-induced lymphoproliferative tumors in severe combined immunodeficient mice are oligoclonal. Blood 79:173.
25. Rochford, R., M. V. Hobbs, J. L. Garnier, N. R. Cooper, and M. J. Cannon. 1993. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc. Natl. Acad. Sci. USA 90:352.
26. + T cell response to Epstein-Barr virus (EBV): implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood 91:3875.
27. Banchereau, J., P. de Paoli, A. Valle, E. Garcia, and F. Rousset. 1991. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251:70.
28. + T cell responses by E7-pulsed autologous dendritic cells in patients with HPV16 and HPV18-positive cervical cancer. J. Virol. 73:5402.
29. Tanimoto, H., Y. Yan, J. Clarke, S. Korourian, K. Shigemasa, T. H. Parmley, G. P. Parham, and T. J. O'Brien. 1997. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed on ovarian cancer. Cancer Res. 57:2884.
30. Luo, J., D. J. Duggan, Y. Chen, J. Sauvageot, C. M. Ewing, M. L. Bitmer, J. M. Trent, and W. B. Isaacs. 2001. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61:4683.
31. Magee, J. A., T. Araki, S. Patil, T. Ehrig, L. True, P. A. Humphrey, W. J. Catalona, M. A. Watson, and J. Milbrandt. 2001. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 61:5692.
32. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156.
33. Rochford, R., M. J. Cannon, R. E. Sabbe, K. Adusumilli, G. Picchio, J. Glynn, D. J. Noonan, D. E. Mosier, and M. V. Hobbs. 1997. Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines. Viral Immunol. 10:183.
34. + T cells from young and old mice. J. Immunol. 150:3602.
35. Rochford, R., and D. E. Mosier. 1995. Differential Epstein-Barr virus gene expression in B-cell subsets recovered from lymphomas in SCID mice after transplantation of human peripheral blood lymphocytes. J. Virol. 69:150.
36. Wang, F., C. D. Gregory, M. Rowe, A. B. Rickinson, D. Wang, M. Birkenbach, H. Kikutani, T. Kishimoto, and E. Kieff. 1987. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc. Natl. Acad. Sci. USA 84:3452.
37. Wang, F., C. Gregory, C. Sample, M. Rowe, D. Liebowitz, R. Murray, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:2309.
38. Calderhead, D. M., Y. Kosaka, E. M. Manning, and R. J. Noelle. 2000. CD40-CD154 interactions in B-cell signaling. Curr. Top. Microbiol. Immunol. 245:73.
39. + T-cells from Epstein-Barr virus (EBV) seropositive donors. Clin. Exp. Immunol. 126:101.
40. + T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J. Virol. 75:3740.
41. + cytotoxic T lymphocytes, Eur. J. Immunol. 23:418.
42. Van De Wiel-Van Kemenade, E., A. A. Te Velde, A. J. De Boer, R. S. Weening, A. Fischer, J. Borst, C. J. Melief, and C. G. Figdor. 1992. Both LFA-1-positive and -deficient T cell clones require CD2/LFA-3 interaction for specific cytolytic activation. Eur. J. Immunol. 22:1467.
43. Gregory, C. D., R. J. Murray, C. F. Edwards, and A. B. Rickinson. 1988. Down-regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J. Exp. Med. 167:1811.
44. Wendel-Hansen, V., A. Rosen, and G. Klein. 1987. EBV-transformed lymphoblastoid cell lines down-regulate EBNA in parallel with secretory differentiation. Int. J. Cancer 39:404.
45. Delecluse, H. J., E. Kremmer, J. P. Roualt, C. Cour, G. Bornkamm, and F. Berger, 1995. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am. J. Pathol. 146:1113.
46. Frizzera, G., D. W. Hanto, K. J. Gajl-Peczalska, J. Rosai, R. W. McKenna, R. K. Sibley, K. P. Holahan, and L. L. Lindquist. 1981. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant patients. Cancer Res. 41:4262.
47. Nalesnik, M. A., R. Jaffe, T. E. Starzl, A. J. Demetris, K. Porter, J. A. Burnham, L. Makowka, M. Ho, and J. Locker. 1988. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporin A-prednisone immunosuppression. Am. J. Pathol. 133:173.
48. Cen, H., P. A. Williams, H. P. McWilliams, M. C. Breinig, M. Ho, and J. L. McKnight. 1993. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 81:1393.
49. Burdin, N., C. Van Kooten, L. Galibert, J. S. Abrams, J. Wijdenes, J. Banchereau, and F. Rousset. 1995. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J. Immunol. 154:2533.
50. Rousset, F., E. Garcia, and J. Banchereau. 1991. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J. Exp. Med. 173:705.
51. Rousset, F., E. Garcia, T. DeFrance, C. Peronne, N. Vezzio, D. H. Hsu, R. Kastelein, and K. W. Moore. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 89:1890.
52. Cooper, N., R. Rochford, J. L. Garnier, M. Cirone, M. Hobbs, and M. Cannon. 1993. The SCID/hu model of EBV-induced human B cell lymphoproliferative disease: insights for diagnosis, prevention and treatment: proceedings of the Vth International Symposium on Epstein-Barr Virus and Related Diseases. Colloq. INSERM 225:541.
53. Masucci, M. G., Q. J. Zhang, R. Gavioli, P. O. de Campos-Lima, R. J. Murray, J. Brooks, H. Griffin, H. Ploegh, and A. B, Rickinson. 1992. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells. Int. Immunol. 4:1283.
54. Griffin, H., M. Rowe, R, Murray, J. Brooks, and A. Rickinson. 1992. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition. Eur. J. Immunol. 22:1741.
55. Altmeyer, A., R. C. Simmons, S. Krajewski, J. C. Reed, G. W. Bornkamm, and S. Chen-Kiang. 1997. Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation. Immunity 7:667.
56. Tosato, G., J, Tanner, K. D. Jones, M. Revel, and S. E. Pike. 1990. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J. Virol. 64:3033.
57. Burdin, N., C. Peronne, J. Banchereau, and F. Rousset. 1993. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J. Exp. Med. 177:295.
58. Beatty, P. R., S. M. Krams, and O. M. Martinez. 1997. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J. Immunol. 158:4045.
59. Birkeland, S. A., K. Bendtzen, B. Moller, S. Hamilton-Dutoit, and H. K. Andersen. 1999. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 67:871.
60. Martinez, O. M., J. C. Villanueva, L. Lawrence-Miyasaki, M. B. Quinn, K. Cox, and S. M. Krams. 1995. Viral and immunologic aspects of EBV infection in pediatric liver transplant patients. Transplantation 59:519.
61. Mathur, A., D. M. Kamat, A. H. Filipovich, M. Steinbuch, and R. S. Shapiro. 1994. Immunoregulatory abnormalities in patients with EBV-associated B cell lymphoproliferative disorders. Transplantation 57:1042.
62. Nalesnik, M. A., A. Zeevi, P. S. Randhawa, A. Faro, K. J. Spichty, A. J. Demetris, J. J. Fung, T. L. Whiteside, and T. E. Starzl. 1999. Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clin. Transplant. 13:39.
63. Tosato, G., K. Jones, M. C. Breinig, H. P. McWilliams, and J. L. McKnight. 1993. Interleukin-6 production in posttransplant lymphoproliferative disease. J. Clin. Invest. 91:2806.